An interventional study of Voriconazole (therapeutic drug monitoring) in Mycoses, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-02-22.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment
The purpose of this study is to determine whether therapeutic drug monitoring of voriconazole is useful in the treatment of invasive fungal infection.
Voriconazole is an anti-fungal agent, which is used in the treatment of invasive fungal infection, especially aspergillosis. The serious side effects of voriconazole include liver function abnormality, encephalopathy, etc. Recently, the several studies showed that the blood level of voriconazole is variable and it is associated with drug side effect and treatment outcome. However, there is no randomized controlled study which proves that therapeutic drug monitoring of voriconazole can improve the clinical outcome in routine clinical practice.
539 studies on the registry are indexed under Mycoses; 55 are open to participants now.
This study's enrollment of 110 is above the median of 46 across 358 interventional studies indexed under Mycoses.
Browse Mycoses studies →Seoul National University Hospital is the lead sponsor of 1,859 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
conventional dose
Drug: Voriconazole (therapeutic drug monitoring)
dosage adjustment according to trough level of voriconazole in plasma
Also known as: plasma drug level
side effects
Time frame: during 3 months
treatment response to voriconazole
Time frame: at 3 months
drug discontinuation of adverse events
Time frame: within 3 month
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital